Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial.

ABSTRACT:

Background

To evaluate the efficacy of 1% and 2% rebamipide clear solution in the treatment of dry eye disease (DED).

Methods

Two hundred twenty patients with DED were randomly assigned to one of three groups: the 1% rebamipide, 2% rebamipide, or placebo (eye drops containing the same ingredients, except for the active components). Each eye drop was instilled four times daily for 12 weeks. Changes in tear film break-up time (TBUT), corneal and conjunctival staining score, Schirmer 1 test, and the Ocular Surface Disease Index (OSDI) from baseline to 12-week visit between the study groups were compared for efficacy assessment.

Results

The mean age of study patients was 43.8±14.2 years. The 1% and 2% rebamipide groups showed greater improvement in TBUT (1.99±1.87 and 2.0

SUBMITTER: Eom Y 

PROVIDER: S-EPMC10398964 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature